Penn Researchers Develop Novel Platform to More Efficiently Produce mRNA Delivery Particles
This new method not only allows for rapid production but also enables precise targeting the LNPs to specific organs like the liver, lungs and spleen.
Penn Medicine researchers use AI to uncover potential antibiotic compounds
The researchers used AI to analyze the genomes of tens of thousands of bacteria and other primitive organisms.
Penn Engineers Unlock the Potential for a New Generation of Wireless Communications
Researchers , have developed an adjustable high frequency filter that prevents signal interference in wireless communications and data transfers.
New Mini-documentary Showcases the Path to CAR-T Cell Therapy
This short documentary tells the powerful story of Bruce Levine, PhD, the Barbara and Edward Netter Professor in Cancer Gene Therapy at Penn Medicine, and the successful use of CAR-T cell therapy.
Penn Engineering Faculty Attend AI & Energy Summit in Pittsburgh
Penn Engineering faculty showcased Penn research, technologies, and start-up companies in the fields of energy, AI and computing.
Penn Medicine Highlights Public Funding’s Role in Translating Scientific Discoveries into Life-Saving Treatments
Stephen Bagley, MD, MSCE, Assistant Professor of Hematology-Oncology and Neurosurgery at Penn Medicine, discusses how he used CAR T cell therapy to shrink a patient's tumor.
Nicholas Siciliano, Chief Executive Officer and Co-Founder of Penn Spinout ViTToria Biotherapeutics, Wins the Science Center’s 2025 Commercialization Award
Siciliano won the Science Center’s 2025 Commercialization Award in recognition of his outstanding contributions to the commercialization of innovative science and technology.
Avisi Technologies Present Promising Clinical Data at the American Glaucoma Society
Avisi is based on technology invented by Igor Bargatin, PhD, Associate Professor of Mechanical Engineering and Applied Mechanics at Penn Engineering.
Apellis’ Empaveli® Gains FDA Approval for Broader Rare Kidney Disease Use
Penn spinout Apellis received FDA approval for an expanded label for Empaveli®.
Carisma Therapeutics Enters into Definitive Merger Agreement with OrthoCellix to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases
Carisma Therapeutics, co-founded by Saar Gill, MD, PhD, Associate Professor of Medicine at Penn Medicine, is merging with OrthoCellix.